A phase i pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide G3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 14, Issue 9, 2008, Pages 2732-2739

  Liu, Glenn ^a   Kolesar, Jill ^a   McNeel, Douglas G ^a   Leith, Catherine ^b   Schell, Kathy ^a   Eickhoff, Jens ^b   Lee, Fred ^b   Traynor, Anne ^a   Marnocha, Rebecca ^a   Alberti, Dona ^a   Zwiebel, James ^c   Wilding, George ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; OBLIMERSEN; PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BAX PROTEIN, HUMAN; NUCLEOTIDE;

ABDOMINAL PAIN; ADVANCED CANCER; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOKALEMIA; HYPOTENSION; HYPOXIA; ILEUS; INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MENTAL HEALTH; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTOVAGINAL FISTULA; SIDE EFFECT; SOLID TUMOR; SUPRAVENTRICULAR TACHYCARDIA; SYNCOPE; THROMBOCYTOPENIA; TUMOR BIOPSY; DOWN REGULATION; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASM; PROTO ONCOGENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; CARBOPLATIN; COMBINED MODALITY THERAPY; DOWN-REGULATION; FEMALE; GENE EXPRESSION; GENES, BCL-2; HUMANS; MALE; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; THIONUCLEOTIDES;

EID: 52049093474     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1490     Document Type: Article

References (42)

1. McDonnellTJ.Troncoso P, Brisbay SM, et al. Expression of the prooncogene Bcl-2 in the prostate and its associaion witht he emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-4.
2. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancer. Am J Pathol 1993;143:390-400.
3. Cerroni L, Soyer HP, Kerl H. Bcl-2 protein expression in cutaneous malignant melanoma and benign melanoctic nevi. Am J Dermatopathol 1995;17:7-11.
4. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Hans AL. Bcl-2 in normal human breast and carcinoma, association with estrogen receptor-positive, epidermal growth factor receptor-negative tumors in situ cancer. Br J Cancer 1994;69:135-9.
5. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993; 329:690-4.
6. Chandler D, el-Naggar AK, Brisbay S, Redline RW, McDonnell TJ. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol 1994;25:789-96.
7. Preethi TR, Chacko R, Kesari AL, Praseeda I, Chellam VG, Pillai MR. Apoptosis in epithelial ovarian tumors. Pathol Res Pract 2002;198:273-80.
8. Fisher TC, Milner AE, Gregory CD, et al. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res 1993:53:3321 -6.
9. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol Oncol Clin N Am 1995;9:451 -74.
10. Kitada S, Miyashita T.Tanaka S, Reed JC. Investigations of antisense oligonucleotides targeted against Bcl-2 mRNAs. Antisense Res Dev 1993;3:157-69.
11. Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodg-kin's lymphoma. J Clin Oncol 2000;18:1812-23.
12. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the oblimersen melanoma study group. J Clin Oncol 2006;24:4738-44.
13. Rudin CM, Kozloff M, Hoffman PC, et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004;22:1110-7.
14. TM G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 2006;17:313-21.
15. Marshall J, Chen H.Yang D, et al. A phase I trial of Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004;15:1274-83.
16. Chi KN, Gleave ME, Klase R et al. A phase dosefinding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001; 7:3920-7.
17. Morris MJ.Tong WP, Cordon-Cardo C, etal. Phase I trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intraveneous infusion in patients with advanced cancer. Clin Cancer Res 2002;8:679-83.
18. Scatena CD, Stewart ZA, Mays D, et al. Mitotic phosphorylation of bcl-2 during normal cell cycle progression and taxol-induced growth arrest. J Biol Chem 1998;273:30777-84.
19. Haldar S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
20. Cheng SC, Luo D, XieY. Taxol induced bcl-2 protein phosphorylation in human hepatocellular carcinoma QGY-7703 cell line. Cell Biol Int 2001;25:261 -5.
21. Luo D, Cheng SC, XieY. Expression of Bcl-2 family proteins during chemotherapeutic agents-induced apoptosis in the hepatoblastoma HepG2 cell line. Br J Biomed Sci 1999;56:114-22.
22. Rodi DJ, Janes RW, Sanganee HJ, Holton RA, Wallace BA, Makowski L. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. J Mol Biol 1999;285:197-203.
23. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense Bcl-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000; 86:855-62.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumors. J Natl Cancer Inst 2000;92:201 -16.
25. Tolcher AW, Kuhn J, Schwartz G, et al. A phase I pharmacokinetic and biological correlative study of oblimersen sodium (Genasense, G3139), an antisense oligonucleotide to the bcl-2 mRNA, docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 2004;10:5048-57.
26. Marcucci G, Stock W, Dai G, et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005;23:3404-11.
27. Obasaju CK, Johnson SJ, Rogatko A, et al. Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel. Clin Cancer Res 1996;2:548-52.
28. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533-44.
29. Kurata T,Tamura T, Shinkai T, et al. Phase I and pharmacological study of paclitaxel given over 3 hours with cisplatin for advanced non small cell lung cancer. Jpn J Clin Oncol 2001;31:93-9.
30. Chadderton T, Wilson C, Bewick M, Gluck S. Evaluation of three rapid RNA extraction reagents: relevance for use in RT-PCR's and measurement of low level gene expression in clinical samples. Cell Mol Biol (Noisy-le-grand) 1997;43:1227-34.
31. Meadows SM, Mulkerin D, Berlin J, et al. Phase II trial of perillyl alcohol in patients with metastatic colorectal cancer. Int J Gastrointest Cancer 2002;32:125-8.
32. Herrington JD, Tran HT, Riggs MW. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or = 27 or cachexia. Cancer Chemother Pharmacol 2006;57:241 -7.
33. Klasa RJ, Gillum AM, Klem RE, et al. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12:193-213.
34. Rudin CM, Holmlund J, Flemming GF, et al. Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res 2001;7:1214-20.
35. Cunningham CC, Holmlund JT, Geary RS, et al. A phase I trial of H-ras antisense oligonucleotide ISIS 2503 administered as a continuous intraveneous infusion in patients with advanced cancer. Cancer 2001;92:1265-71.
36. Yuen AR, Halsey J, Fisher GA, et al. Phase I study of an antisense oligonucleotide to protein kinase c-a (ISIS 3521/CGP 64128A) in patients with cacner. Clin Cancer Res 1999;5:3357-63.
37. Rudin CA, Kozloff M, Hoffman PC, et al. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol 2004;22:1110-7.
38. Mita MM, Ochoa L, Rowinsky EK, et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 2006;17:313-21.
39. MarshallJ, Chen H.Yang D, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004;15:1274-83.
40. Kitada S, MiyashitaT,Tanaka S, Reed JC. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Res Dev 1993;3:157-69.
41. Van De Wiele C. Vermeersch H, Loose D, Signore A, Mertens N, Dierckx R. Radiolabeled annexin-V for monitoring treatment and response in oncology. Cancer Biother Radiopharm 2004;19:189-94.
42. Gekeler V, Gimmnich P, Hofmann HP, et al. G3139 and other CpG-containing immunostimulatory phosphorothiolate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenographs in nude mice. Oligonucleotides 2006;16:83-93.